JP2011528222A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528222A5
JP2011528222A5 JP2011517723A JP2011517723A JP2011528222A5 JP 2011528222 A5 JP2011528222 A5 JP 2011528222A5 JP 2011517723 A JP2011517723 A JP 2011517723A JP 2011517723 A JP2011517723 A JP 2011517723A JP 2011528222 A5 JP2011528222 A5 JP 2011528222A5
Authority
JP
Japan
Prior art keywords
rsv
polypeptide
chimeric
amino acid
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2009/001021 external-priority patent/WO2010006447A1/en
Publication of JP2011528222A publication Critical patent/JP2011528222A/ja
Publication of JP2011528222A5 publication Critical patent/JP2011528222A5/ja
Pending legal-status Critical Current

Links

JP2011517723A 2008-07-18 2009-07-17 キメラ呼吸器合胞体ウイルスポリペプチド抗原 Pending JP2011528222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8188808P 2008-07-18 2008-07-18
US61/081,888 2008-07-18
PCT/CA2009/001021 WO2010006447A1 (en) 2008-07-18 2009-07-17 Chimeric respiratory syncytial virus polypeptide antigens

Publications (2)

Publication Number Publication Date
JP2011528222A JP2011528222A (ja) 2011-11-17
JP2011528222A5 true JP2011528222A5 (enExample) 2012-09-06

Family

ID=41549978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517723A Pending JP2011528222A (ja) 2008-07-18 2009-07-17 キメラ呼吸器合胞体ウイルスポリペプチド抗原

Country Status (13)

Country Link
US (1) US20110177117A1 (enExample)
EP (1) EP2324062A4 (enExample)
JP (1) JP2011528222A (enExample)
KR (1) KR20110045008A (enExample)
CN (1) CN102131830A (enExample)
AU (1) AU2009270399A1 (enExample)
BR (1) BRPI0915960A2 (enExample)
CA (1) CA2731194A1 (enExample)
EA (1) EA201170217A1 (enExample)
IL (1) IL210493A0 (enExample)
MX (1) MX2011000668A (enExample)
WO (1) WO2010006447A1 (enExample)
ZA (1) ZA201100132B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563002B2 (en) * 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
CN103533954B (zh) * 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
AU2014228765A1 (en) * 2013-03-15 2015-10-15 Medimmune, Llc Palivizumab epitope-based virus-like particles
WO2014170258A1 (en) * 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
AU2014255864B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
EP2873708B1 (de) 2013-11-19 2019-02-13 Artimelt AG Klebstoffzusammensetzung
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
SG10202108573TA (en) * 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Kmバイオロジクス株式会社 Rsv f/gキメラワクチン
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
CN122180699A (zh) * 2023-08-03 2026-06-09 广州宾和企业管理合伙企业(有限合伙) 修饰的呼吸道合胞病毒f蛋白及其用途
WO2025263563A1 (ja) * 2024-06-20 2025-12-26 Kmバイオロジクス株式会社 RSV FGキメラmRNAワクチン
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69313134T2 (de) * 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) * 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
FR2873378A1 (fr) * 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
US8563002B2 (en) * 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens

Similar Documents

Publication Publication Date Title
US12364749B2 (en) RSV F protein mutants
USRE47471E1 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CA2187083C (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
JP2010522540A5 (enExample)
JP7385680B2 (ja) 変異型rsv fタンパク質及びその利用
JP2012530761A5 (enExample)
HRP20161353T1 (hr) Rekombinantni rsv antigeni
RU2014117068A (ru) Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
JP2010508030A5 (enExample)
JP2015509707A5 (enExample)
EP3638284B1 (en) Cyclic peptides for protection against respiratory syncytial virus
JP7146926B2 (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
WO2025156779A1 (zh) 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
JP2011505164A5 (enExample)
CN101879312B (zh) 广谱型流感疫苗及其制备方法
CN113769080B (zh) 多肽免疫偶联物及其应用
CN102397559A (zh) 广谱型流感疫苗及其制备方法
CN105233302B (zh) 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
US20230355737A1 (en) Particle comprising an rsv-f protein for use in rsv vaccination
RU2788403C2 (ru) Мутанты белка f rsv
RU2022102876A (ru) Поливалентная иммуногенная композиция против папилломавируса человека
Samal et al. https://www. jbc. org/cgi/doi/10.1074/jbc. RA120. 013233 The latest version is at